STOCK TITAN

Caredx - CDNA STOCK NEWS

Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.

CareDx Inc (CDNA) delivers innovative non-invasive diagnostics for transplant patient care through advanced genomics and bioinformatics. This news hub provides investors and healthcare professionals with essential updates on the company's developments in precision medicine.

Key resources include: Earnings reports detailing financial performance in transplant diagnostics, regulatory updates on FDA-cleared testing solutions, and strategic partnership announcements expanding into hematology oncology. Track clinical trial outcomes validating AlloSure® monitoring and discover operational milestones in digital health integration.

Our curated collection enables efficient tracking of CDNA's progress in reducing invasive biopsies through blood-based dd-cfDNA analysis. Stay informed about innovations in kidney, heart, and lung transplant surveillance technologies that are reshaping organ rejection management.

Bookmark this page for real-time updates on CareDx's evidence-based diagnostic solutions and their impact on transplant care standards. Verify analysis dates and consult official filings for complete context on all developments.

Rhea-AI Summary

CareDx, Inc. (NASDAQ: CDNA) has announced it will report its financial results for the fourth quarter and full year 2022 on February 27, 2023, after market closure. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET for management to discuss the results. Interested parties can join the call by dialing 1-877-704-4453 (domestic) or 1-201-389-0920 (international), referencing Conference ID: 13736063. CareDx specializes in precision medicine solutions for transplant patients, delivering testing services and products throughout the patient journey.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
conferences earnings
-
Rhea-AI Summary

CareDx, a precision medicine company, is set to present its innovative solutions for cellular transplant and therapy at the 2023 Tandem Meetings from February 15-19 in Orlando, Florida. CEO Reg Seeto emphasized the importance of these advancements in cell therapy monitoring and digital health. Notable presentations include AutoCell™, a high-sensitivity solution for CAR-T cell monitoring, and various digital health solutions aimed at improving patient care across transplant centers. CareDx's offerings include workflow management, medication adherence solutions, and remote monitoring tools designed for effective patient engagement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
-
Rhea-AI Summary

CareDx, Inc. (CDNA) announced the publication of a guide in the Journal of the American College of Cardiology to assist clinicians in transitioning from invasive endomyocardial biopsies (EMB) to non-invasive monitoring for heart transplant rejection using AlloMap GEP and AlloSure dd-cfDNA. The guide highlights the clinical utility of these non-invasive tests, emphasizing their effectiveness in rejection surveillance. CareDx's HeartCare services are now utilized in over 90% of U.S. heart transplant centers, reflecting a growing trend towards non-invasive practices in heart transplant monitoring.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
Rhea-AI Summary

CareDx (NASDAQ: CDNA) announced its participation as a Distinguished Founder’s Circle Sponsor at the 23rd Annual ASTS State of the Art Winter Symposium from January 12-15, 2023, in Miami, Florida. This marks the fourth consecutive year for CareDx at this event, emphasizing their commitment to innovation in transplant patient care. The company will host a symposium on January 13 to present advancements in molecular surveillance and digital health solutions. CareDx’s products, like AlloMap and AlloSure, are widely used in transplant centers across the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.23%
Tags
none
-
Rhea-AI Summary

CareDx, Inc. (NASDAQ: CDNA) reported preliminary financial results for Q4 and full year 2022, highlighting record revenues between $81.9 million and $82.2 million, marking a 4% year-over-year growth. Cash collections reached 110% of revenue, a 10% increase, while patient test results rose by 14%. The company maintained a strong cash position of approximately $292 million with no debt. For FY 2022, revenue is expected to be between $321.3 million and $321.6 million, indicating an 8% growth. CareDx plans to focus on pipeline catalysts and increased collections in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.6%
Tags
none
-
Rhea-AI Summary

CareDx, Inc. announces that the International Society for Heart and Lung Transplantation (ISHLT) has updated its guidelines, recommending the earlier use of AlloMap Heart for heart transplant patients starting 2 months post-transplant. The new guidelines endorse donor-derived cell-free DNA (dd-cfDNA) testing for routine monitoring, promoting non-invasive methods to minimize biopsies and hospital visits. These changes reflect the clinical advancements in the last decade and are supported by significant uptake in heart transplant centers nationwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
none
Rhea-AI Summary

CareDx, Inc. (NASDAQ: CDNA) has announced a stock repurchase program authorized by its Board of Directors, allowing for up to $50 million in stock buybacks over 24 months. The program enables discretionary purchases via open market repurchases, private transactions, and trading plans. CEO Reg Seeto expressed confidence in the company's financial position and growth prospects, stating that share buybacks reflect their commitment to long-term shareholder value. The repurchases will utilize existing cash and future cash flow.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.27%
Tags
buyback
-
Rhea-AI Summary

CareDx, Inc. (Nasdaq: CDNA) announced the results of a significant study in the Transplantation Direct journal, establishing a reference baseline for using AlloSure® Lung in lung transplant patient surveillance. Conducted at Vanderbilt University Medical Center, the study involved 51 patients and defined a 73% reference change value for AlloSure dd-cfDNA levels two years post-transplant. This data underscores the clinical utility of AlloSure Lung, currently utilized by 60% of lung centers, as a vital tool amid high lung graft failure rates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
none
-
Rhea-AI Summary

CareDx, Inc. (Nasdaq: CDNA) celebrated the five-year anniversary of AlloSure, a non-invasive solution for monitoring organ transplant health. The company emphasized its leadership in transplant research, with over 100 peer-reviewed publications supporting the clinical use of AlloSure and AlloMap. Having invested more than $200 million in research over the past three years, CareDx continues to enhance transplant outcomes, addressing the significant need for accurate biomarkers in organ transplants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.1%
Tags
none
Rhea-AI Summary

CareDx, Inc. (Nasdaq: CDNA), a leader in precision medicine for transplant patients, will participate in two investor conferences. The first presentation is at the Credit Suisse 31st Annual Healthcare Conference on November 9, 2022, at 1:25 PM ET, accessible via their website. The second is at the Jefferies London Healthcare Conference on November 15, 2022, at 8:30 AM ET. CareDx aims to enhance healthcare solutions for transplant patients and caregivers through innovative testing services and digital solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.47%
Tags
conferences
Caredx

Nasdaq:CDNA

CDNA Rankings

CDNA Stock Data

976.60M
53.24M
3.37%
94.9%
9.34%
Diagnostics & Research
Services-medical Laboratories
Link
United States
BRISBANE